Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Genmab
iOnctura
Suzhou BlueHorse Therapeutics Co., Ltd.
Shanghai Juncell Therapeutics
Inhibrx Biosciences, Inc
Tesaro, Inc.
Toray Industries, Inc
Iovance Biotherapeutics, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Eli Lilly and Company
Nektar Therapeutics
Altor BioScience
Point Therapeutics